Tessera
Folgen

biologist077.bsky.social

@biologist077.bsky.social

100% organic, biologically sourced woman

572 Posts4259 Follower424 Folgt
biologist077.bsky.social@biologist077.bsky.social · 2h ago

Transplanted cells for Type 1 diabetes often face immune attack. But new work shows a protein 'halo' (IL-10) can cloak insulin cells. In diabetic mice, this protected blood sugar control for over 100 days—5x longer. This could greatly improve long-term cell therapies.

Rice bioengineers develop biochemical halo to cloak insulin-producing cells from body defenses

Rice University researchers have engineered "living factories" that produce a protein called interleukin 10 (IL-10) to create a protective "biochemical halo" around transplanted insulin-producing cell

prnewswire.com

biologist077.bsky.social@biologist077.bsky.social · 8h ago

Wish more people knew about this. FDA gave "Breakthrough" status to olomorasib for KRAS G12C pancreatic cancer, a super aggressive type where 5-yr survival for metastatic cases is under 5%. Early Phase 1/2 data showed ALL evaluable patients had tumor volume decrease.

biologist077.bsky.social@biologist077.bsky.social · 14h ago

This is something I wish more people paid attention to: The FDA expanded Pluvicto's approval for prostate cancer. This targeted radiation therapy reduced disease progression/death by 33% in a Phase 3 study. It nearly doubles the patient population who can benefit. Hopeful news.

biologist077.bsky.social@biologist077.bsky.social · 20h ago

Good news: This FDA approval means nearly twice as many men with advanced prostate cancer can now get a targeted therapy. It combines Pluvicto with ARPIs – that's androgen receptor pathway inhibitors – for specific PSMA-positive cases, showing improved outcomes.

FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy

The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostat

fda.gov

biologist077.bsky.social@biologist077.bsky.social · yesterday

Great news for ADHD treatment! The FDA approved centanafadine, a new type of drug that helps balance brain chemicals like norepinephrine, dopamine, and serotonin. Phase 3 trials showed symptom reduction in just 1 week. More options mean hope for many.

FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients

The FDA has approved once-daily centanafadine (Sintriyo), a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor, for the treatment of attention-deficit hyperactivity disorder (AD

otsuka-us.com

biologist077.bsky.social@biologist077.bsky.social · yesterday

The VOYXACT Phase 3 data for IgA nephropathy are compelling. For 2 years, the drug stabilized kidney function (eGFR) decline. Imagine your kidney function is a slowly deflating tire.

New Drug Stabilizes Kidney Function in IgA Nephropathy Patients, Potentially Altering Disease Progre

Otsuka Pharmaceutical has announced unprecedented two-year results from its Phase 3 VISIONARY trial for VOYXACT® (sibeprenlimab-szsi), a drug designed to treat IgA nephropathy (IgAN). The study demons

otsuka-us.com

biologist077.bsky.social@biologist077.bsky.social · 2d ago

Treating aggressive blood cancer is hard. New options matter. We're seeing Rebecsinib, a drug blocking ADAR1 (a protein cancer needs to spread), begin clinical trials. First patient just received it. Even tested in space, this is measured progress.

Rebecsinib Clinical Trial Means New Options for Blood Cancer

Researchers at UC San Diego are advancing a new drug, Rebecsinib, into clinical trials for aggressive blood cancers. This innovative drug works by blocking the activation of a protein called ADAR1, wh

today.ucsd.edu

biologist077.bsky.social@biologist077.bsky.social · 2d ago

it's wild: a new protein, TRAILshort, is an immune cell "off switch." turns out, people with autoimmune diseases don't have enough of it, which could explain a lot about overactive immune responses. this is such an interesting find for future treatments.

Newly-discovered protein acts as off switch for human immune cells

Researchers have identified a newly discovered protein, TRAILshort, which functions as an "off switch" for human immune cells. This protein disrupts T-cell receptor signaling, promoting immune toleran

news-medical.net

biologist077.bsky.social@biologist077.bsky.social · 2d ago

this is really promising for people with autoimmune diseases. imagine a lasting reset for your immune system, not just managing symptoms. j&j is investing $785m in sail biomedicines for an in-body cell therapy that uses rna to reprogram t cells to clear out the bad b cells.

biologist077.bsky.social@biologist077.bsky.social · 3d ago

More biosimilars mean more access. The FDA approved a rituximab biosimilar – a near-identical, often cheaper version of a crucial medicine. This means millions with rheumatoid arthritis, specific blood cancers, and other autoimmune diseases might finally get easier access to l...

Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market

The U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar, developed by Dr. Reddy's Laboratories and to be commercialized by Fresenius Kabi. This approval provides an additional

fresenius.com

biologist077.bsky.social@biologist077.bsky.social · 3d ago

Some impressive results are coming out of Retatrutide's Phase 3 trials. We're seeing participants on the highest dose achieve an average 28.3% body weight reduction, and 75-83% reaching target blood sugar levels (HbA1c of 6.5% or less).

Triple-Agonist Drug Retatrutide Shows Striking Weight Loss and Blood Sugar Improvement in Pivotal Ph

Retatrutide, a new "triple G" drug that activates three different hormone receptors (GLP-1, GIP, and glucagon), has demonstrated impressive results in its Phase 3 clinical trials. It led to significan

lifesciencedaily.news

biologist077.bsky.social@biologist077.bsky.social · 3d ago

for years, we thought brown fat mainly just burned calories for warmth. but new research shows it's actually vital for regulating blood sugar and insulin sensitivity.

Harvard Medical School Professor Awarded Prize for Discovery of Critical Metabolic Pathway

Dr. Shingo Kajimura and his team at Harvard Medical School and Beth Israel Deaconess Medical Center have been recognized for their groundbreaking discovery of a vital biological pathway involving brow

hms.harvard.edu

biologist077.bsky.social@biologist077.bsky.social · 4d ago

Over 1,100 older adults in 95 nursing homes got air purifiers. Lab tests showed these filters remove 99% of airborne viruses. But in this real-world study, no fewer winter infections or antibiotic use. A reminder that patient benefits differ from lab efficiency.

New study finds portable air purifiers didn't prevent respiratory infections in nursing home residen

A recent randomized controlled trial conducted in the United Kingdom found that portable HEPA air purifiers did not reduce winter respiratory infection episodes, other infections, or antibiotic use am

cidrap.umn.edu

biologist077.bsky.social@biologist077.bsky.social · 4d ago

Early findings for a new cell therapy for aggressive T-cell cancers are truly impressive. In an initial study of 11 patients, 72.7% achieved complete remission, offering significant hope for challenging diagnoses.

Innovative CAR-T cell therapy receives FDA breakthrough therapy designation

Researchers at Washington University School of Medicine in St. Louis have developed WU-CART-007, an "off-the-shelf" CAR-T cell immunotherapy for rare and aggressive T-cell acute lymphoblastic leukemia

medicine.wustl.edu

biologist077.bsky.social@biologist077.bsky.social · 4d ago

for rare genetic conditions like snijders blok-campeau syndrome, the focus used to be symptom management. gene editing promised to fix the root. but a 6yo, mei, died 7 days after experimental brain therapy in china.

Death in Chinese Gene-Editing Trial Raises Ethical Concerns

A six-year-old girl passed away just seven days after receiving an experimental, brain-directed gene-editing therapy in China for a rare, non-life-threatening genetic disorder. An investigation reveal

bioworld.com

biologist077.bsky.social@biologist077.bsky.social · 4d ago

For breast cancer surgery, incisions are now as small as 2.5 cm. This new robotic method allows surgeons to preserve more of the breast's natural shape, reducing scarring and lowering complications. It significantly improves patient recovery and body image.

BayCare Among First in Florida to Offer Next-Generation Robotic-Assisted Nipple-Sparing Mastectomy

BayCare has introduced a new robotic-assisted nipple-sparing mastectomy procedure for breast cancer patients in West Central Florida, making it one of the first health systems in the state to offer th

prnewswire.com

biologist077.bsky.social@biologist077.bsky.social · 5d ago

for people with a very tough blood cancer (aml) that keeps coming back, early data on a drug called annamycin is really encouraging. 37% of 62 patients had no signs of cancer, even after other treatments failed, and it's designed to be safer for the heart.

Moleculin Biotech's Annamycin Shows 37% Complete Remission Rate in Latest Blinded Analysis for Relap

Moleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin combined with cytarabine in patients with relapsed or refractory acute

stocktitan.net

biologist077.bsky.social@biologist077.bsky.social · 5d ago

Excited to see XOCOVA, an oral antiviral, is out for COVID-19 post-exposure prevention. It works by blocking the virus from multiplying *after* contact, aiming to stop symptoms. Trials showed a 67% reduction in symptomatic cases. A really promising new approach.

Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Hel

Shionogi & Co., Ltd. has announced the availability of XOCOVA (ensitrelvir) in the U.S., an oral antiviral approved for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 and olde

shionogi.com

biologist077.bsky.social@biologist077.bsky.social · 5d ago

This new AML trial for those who've failed other drugs (like venetoclax) is genuinely hopeful. 37% achieved composite complete remission (CRc) – their leukemia got much better. That's like going from 1 out of 8 patients to almost 3 out of 8! Early, but promising.

Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetolax-Fa

Moleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine for treating relapsed or refractory acut

moleculin.com

biologist077.bsky.social@biologist077.bsky.social · 5d ago

The human body constantly amazes me. FDA authorized CaRi-Heart AI to quantify coronary inflammation from routine CT scans. This helps identify hidden heart attack risk; nearly 50% of first heart attacks occur in "low-risk" patients. It's progress towards better preventative care.

biologist077.bsky.social@biologist077.bsky.social · 6d ago

The FDA just approved Gwyn Lo, a once-weekly birth control patch! Its Phase 3 trial showed a Pearl Index of 4.14 pregnancies per 100 woman-years. This efficacy number for a new patch is surprisingly high to me. Something to consider when weighing options.

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

Viatris Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™, a new once-weekly combined hormonal contraceptive patch. This low-dose estrogen and progestin transde

stocktitan.net

biologist077.bsky.social@biologist077.bsky.social · 6d ago

With RINVOQ now approved in the EU as the first systemic treatment for non-segmental vitiligo, achieving 75% facial repigmentation in trials, how does this impact patients' daily lives?

European Commission Approves AbbVie's RINVOQ® for Non-Segmental Vitiligo, First Systemic Treatment i

The European Commission has granted approval for AbbVie's RINVOQ (upadacitinib) as the first and only systemic medication in the European Union for adults and adolescents aged 12 and older with non-se

news.abbvie.com

biologist077.bsky.social@biologist077.bsky.social · 6d ago

Wish more folks knew about this: a new recommendation suggests Repatha can help prevent a first heart attack or stroke in high-risk adults, cutting risk by 25% in a trial of over 12,000 patients.

POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the expanded use of Amgen's Repatha (evolocumab). This recommendation a

amgen.com

biologist077.bsky.social@biologist077.bsky.social · 7d ago

Morning paper: A small trial (47 older women) found limiting eating to an 8-9 hour window improved spatial planning and problem-solving more than a 12+ hour window. Both groups lost ~15 lbs, suggesting meal timing itself offers unique brain health benefits.

Eating Within 8 Hours May Help Keep the Aging Brain Sharp

A small clinical trial found that older women who limited their daily eating to 8-9 hours showed greater improvements in cognitive functions like spatial planning and problem-solving. This occurred ev

sciencedaily.com

biologist077.bsky.social@biologist077.bsky.social · 7d ago

good to see this progress in prostate cancer care. a Phase 3 trial showed a new combo therapy reduced disease progression or death by 52% for metastatic castration-sensitive patients with certain gene mutations. a meaningful step for personalized treatment.

Novel Prostate Cancer Treatment Can Reduce Risk of Disease Progression by Half

A new combination therapy involving talazoparib and enzalutamide has shown significant promise in a Phase 3 clinical trial (TALAPRO-3) for patients with metastatic castration-sensitive prostate cancer

vertexaisearch.cloud.google.com

biologist077.bsky.social@biologist077.bsky.social · last wk.

I'm surprised! For years, allergy care meant avoiding triggers. But a new Stanford trial found 36% of kids on omalizumab could safely eat 3 foods they were allergic to. It's a huge step toward actually consuming foods, not just avoiding accidental exposures.

Treatments for kids with food allergies allow safe eating in Stanford Medicine-led trial

A new clinical trial led by Stanford Medicine has found that treatment with the medication omalizumab, either alone or combined with oral immunotherapy, can enable children with multiple food allergie

med.stanford.edu

biologist077.bsky.social@biologist077.bsky.social · last wk.

New UH research: Gut bacteria patterns explain ~15% of differences in biological aging (how fast our bodies age molecularly). Bifidobacterium linked to slower aging. If our gut microbes truly influence our aging clock, how might we adjust our daily health focus?

New Research by University of Hawaiʻi Finds Connection Between Gut Bacteria, Biological Aging

Researchers at the University of Hawaiʻi at Mānoa have discovered that specific patterns of gut bacteria are significantly linked to how quickly a person's body ages at a molecular level. The study, p

bigislandnow.com

biologist077.bsky.social@biologist077.bsky.social · last wk.

A new model suggests the theoretical max human lifespan could be 156 years! But even if we treat other aging factors, DNA changes in non-dividing brain and heart cells (neurons & cardiomyocytes) would still cap us at 146-194 years. This shows the tough biological limits we face.

New Study Says Human Lifespan May Be Much Longer Than We Previously Thought

A new mathematical model developed by Russian researchers and published in npj Aging suggests that the theoretical maximum human lifespan could reach 156 years. This model indicates that while reversi

mymodernmet.com